

# Shuang G Zhao

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9603732/shuang-g-zhao-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51  
papers

3,741  
citations

27  
h-index

54  
g-index

54  
ext. papers

4,988  
ext. citations

10.5  
avg, IF

4.55  
L-index

#	Paper	IF	Citations
51	The landscape of long noncoding RNAs in the human transcriptome. <i>Nature Genetics</i> , <b>2015</b> , 47, 199-208	36.3	1789
50	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , <b>2018</b> , 174, 758-769.e9	56.2	234
49	The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. <i>Nature Communications</i> , <b>2016</b> , 7, 12791	17.4	152
48	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1663-1672	13.4	138
47	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. <i>Lancet Oncology</i> , <b>2016</b> , 17, 1612-1620	21.7	124
46	DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. <i>Cancer Cell</i> , <b>2015</b> , 28, 97-113	24.3	116
45	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 301-310	9.7	99
44	Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3667-77	12.9	86
43	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. <i>Cancer Research</i> , <b>2017</b> , 77, 1021-1034	10.1	74
42	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , <b>2020</b> , 52, 778-789	36.3	71
41	Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5864-5875	12.9	64
40	Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. <i>Journal of Urology</i> , <b>2017</b> , 197, 662-668	2.5	59
39	Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis. <i>Cancer Research</i> , <b>2017</b> , 77, 960-970	10.1	50
38	Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 116, 179-84	5.3	46
37	Independent surgical validation of the new prostate cancer grade-grouping system. <i>BJU International</i> , <b>2016</b> , 118, 763-769	5.6	39
36	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. <i>JAMA Oncology</i> , <b>2016</b> , 2, 471-80	13.4	38
35	Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. <i>Cancer</i> , <b>2020</b> , 126, 717-724	6.4	36

34	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6721-6730	12.9	35
33	PARP-1 regulates DNA repair factor availability. <i>EMBO Molecular Medicine</i> , <b>2018</b> , 10,	12	35
32	The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. <i>European Urology</i> , <b>2018</b> , 74, 444-452	12.9	35
31	Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. <i>Nature Communications</i> , <b>2020</b> , 11, 3811	17.4	34
30	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2019</b> , 22, 531-538	6.2	32
29	The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1777-86	12.9	30
28	A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer. <i>Translational Oncology</i> , <b>2014</b> , 7, 429-429	4.9	30
27	Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial. <i>Head and Neck</i> , <b>2016</b> , 38 Suppl 1, E1086-96	4.2	28
26	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , <b>2021</b> , 79, 374-383	10.2	28
25	Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. <i>Npj Breast Cancer</i> , <b>2017</b> , 3, 29	7.8	27
24	Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2450-2457	12.9	23
23	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 544-552	13.4	17
22	Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4290-4299	12.9	15
21	Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. <i>Cancer</i> , <b>2019</b> , 125, 3338-3346	6.4	10
20	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5608-5622	12.9	10
19	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3908-3916	12.9	10
18	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2926-2937	2.2	10
17	Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. <i>European Urology Oncology</i> , <b>2019</b> , 2, 405-412	6.7	8

16	Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1141-1149	1.49	6
15	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 646-653	6.2	6
14	Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. <i>BJU International</i> , <b>2017</b> , 120, 351-357	5.6	5
13	Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	5
12	A Signature That May Be Predictive of Early Versus Late Recurrence After Radiation Treatment for Breast Cancer That May Inform the Biology of Early, Aggressive Recurrences. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 108, 686-696	4	5
11	Autoantibody Landscape in Patients with Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6204-6214	12.9	4
10	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. <i>European Urology</i> , <b>2021</b> , 79, 717-721	10.2	4
9	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. <i>European Urology Oncology</i> , <b>2018</b> , 1, 276-282	6.7	4
8	Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 316-323	6.2	3
7	Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. <i>European Urology</i> , <b>2020</b> ,	10.2	2
6	ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 2129-2139	6.1	2
5	Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. <i>Npj Genomic Medicine</i> , <b>2021</b> , 6, 76	6.2	2
4	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1644-1652	13.4	2
3	SV-HotSpot: detection and visualization of hotspots targeted by structural variants associated with gene expression. <i>Scientific Reports</i> , <b>2020</b> , 10, 15890	4.9	1
2	SEEMLIS: a flexible semi-automated method for enrichment of methylated DNA from low-input samples.. <i>Clinical Epigenetics</i> , <b>2022</b> , 14, 37	7.7	0
1	Reply to M. K. Bos et al. <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2102238	2.2	